戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  adapt to and cope with oxidative damage and immune clearance.
2 hances the ability of fungal cells to resist immune clearance.
3 developed extensive mechanisms to evade host immune clearance.
4 P can produce priority effects that resemble immune clearance.
5 phagocytic signal and thus activating innate immune clearance.
6 nd memory T cells that are then critical for immune clearance.
7  mechanisms employed by T. pallidum to avoid immune clearance.
8 ollicles (BCFs), exposing infected cells for immune clearance.
9  resistance to antimicrobial agents and host immune clearance.
10 ivating human prothrombin (ProT) and evading immune clearance.
11 njury remains challenging due to circulatory immune clearance.
12 nd resensitizing the pathogen to host innate immune clearance.
13 oevasive strategy used by the virus to avoid immune clearance.
14 C3-coated particles, a function critical for immune clearance.
15  Nef's activities and sensitize the virus to immune clearance.
16 sponse, employs multiple mechanisms to evade immune clearance.
17 ivating inflammation and by interfering with immune clearance.
18 sues, adhesion to host cells, and evasion of immune clearance.
19 CR1, and suggest that C1q may participate in immune clearance.
20  contribute to the ability of HCMV to escape immune clearance.
21 nce represent functional mechanisms to evade immune clearance.
22 ique and highly effective mechanism to avoid immune clearance.
23 BRCA1/2-mutant tumors, are rewired to escape immune clearance.
24 ses, leading to viral cytopathic effects and immune clearance.
25 s infecting dose either lead to infection or immune clearance?
26 rface-exposed antigens-is a major barrier to immune clearance(1).
27  induce tumours, in part owing to OIS-driven immune clearance(3).
28 gen virulence, and do not necessarily signal immune clearance ability.
29 nteractions that enable this virus to escape immune clearance and cause immunodeficiency.
30 loys an array of effector proteins to escape immune clearance and ensure latent survival.
31 m used by bacterial pathogens to escape host immune clearance and establish persistent infection.
32 ariation allows microbial pathogens to evade immune clearance and establish persistent infection.
33 igenically variant surface proteins to evade immune clearance and establish persistent infection.
34  which form intracellular cysts resistant to immune clearance and existing therapies.
35 critical functions of its host cell to avoid immune clearance and gain access to nutritional resource
36 rferi to determine the role of complement in immune clearance and joint histopathology during experim
37 iration, which is balanced by mechanical and immune clearance and likely involves limited local repli
38  display no additional properties related to immune clearance and persistence within relevant hosts.
39 onized particles and provide a mechanism for immune clearance and phagocytosis of IgG-coated particle
40  T cells, a few virus-infected cells escaped immune clearance and progressed to HCC.
41 rier, the use of stealth coatings can reduce immune clearance and prolong circulatory times, thereby
42 developed a sophisticated machinery to evade immune clearance and promote survival in the infected ce
43                                              Immune clearance and resource limitation (via red blood
44 hesized that individual TprK variants escape immune clearance and seed new disseminated lesions to ca
45 les (NPs) to specific sites requires evading immune clearance and selectively binding target cells.
46 ntercellular cohesion and protecting against immune clearance and stress in circulation.
47 lly relevant model of HBV infection to study immune clearance and test therapeutic and curative appro
48 ate immune function allows them to undermine immune clearance and thereby increase their persistence
49 axis allowed it to escape IL-12p70-dependent immune clearance and to cause inflammatory bone loss in
50 d core protein of wild-type genotype C delay immune clearance and trigger the subsequent emergence of
51  associated with failures of T-cell-mediated immune clearance and with abnormal B-cell growth and act
52 fect the gastric mucosal surface, evade host immune clearance, and cause peptic ulcer disease or gast
53 t of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung t
54 zed the nasal tropism of SARS-CoV-2 strains, immune clearance, and regeneration after infection.
55 oreover, the gCM shell protects the MNs from immune clearance; and in turn, the MN core delivers the
56 vive in hosts and escape complement-mediated immune clearance, Bb produces the outer surface protein
57              African trypanosomes evade host immune clearance by antigenic variation, causing persist
58 fection in the host, most likely in avoiding immune clearance by cytotoxic lymphocytes and natural ki
59 ver an acquired capability of GSCs to escape immune clearance by establishing an enhanced immunosuppr
60 r cells to the stroma to abrogate tumor cell immune clearance by killer T lymphocytes.
61   The virus has evolved strategies to escape immune clearance by remaining latent in most infected ce
62 ntigen-presenting cells and evades effective immune clearance by the adaptive response through (i) ma
63 esting a common mechanism of protection from immune clearance by their hosts.
64 tance factor, which is involved in resisting immune clearance, contributes to E faecalis fitness.
65 r NS5A, which regulates virus production and immune clearance early in therapy.
66 80 should render the parasite susceptible to immune clearance from the host by both providing a focus
67 as consisting of 4 phases: immune tolerance, immune clearance [hepatitis B e antigen (HBeAg)-positive
68 g successfully developed mechanisms to evade immune clearance, hepatitis C virus (HCV) establishes pe
69 sions and Relevance: Increased resistance to immune clearance in an ESBL E coli lineage already known
70 the ability of P. aeruginosa to avoid innate immune clearance in mammals is a type III secretion syst
71 t mice to examine the role of FcgammaRIIA in immune clearance in the absence of functional FcgammaRI
72 mes less hepatocyte turnover occurred during immune clearance in the ETV-treated woodchucks.
73 izes NDM-1-producing K. pneumoniae to innate immune clearance in ways that are not appreciated by sta
74 sized that this flagellated pathogen escapes immune clearance, in part, by avoiding detection by the
75 vel strategy for Salmonella evading the host immune clearance, in which Salmonella produce microRNA-l
76                      Host resistance through immune clearance is predicted to favor pathogens that ar
77 es that aim to induce viral reactivation for immune clearance leverage latency reversal agents to mod
78 robably require potent suppression of innate immune clearance mechanisms (e.g., by replacement of ade
79 isease pathogenesis by interfering with host immune clearance mechanisms or by exhibiting pro-inflamm
80 capsule expression, and resistance to innate immune clearance mechanisms.
81 lation of LPS facilitates resistance to host immune clearance mechanisms.
82          The nanocapsules exhibit negligible immune clearance, minimal inflammatory response, and eff
83 egs, protect breast cancer cells (BCCs) from immune clearance MSCs suppressed the proliferation of PB
84 nes and decrease proapoptotic genes, improve immune clearance of Abeta, and are associated with an im
85 mitochondrial depolarization, apoptosis, and immune clearance of cancer cells by antitumor leukocytes
86  high rates of changes were found during the immune clearance of chronic hepatitis B infection.
87  system plays a key role in opsonization and immune clearance of engineered nanoparticles.
88 g sialoglycan-Siglec interactions to improve immune clearance of HIV-infected cells.
89                          The microanatomy of immune clearance of infected brain cells remains poorly
90 erein, we assess the effect of venetoclax on immune clearance of infected cells and show that BCL-2 i
91 pothesized that the HIV protein Nef subverts immune clearance of infected cells by downregulating sur
92 molecules that destabilize latency and allow immune clearance of infected cells could lead to treatme
93 cted cells overall, maybe reflecting greater immune clearance of infected cells.
94 mber of groups have investigated whether the immune clearance of infection can be achieved through a
95                  Recent excitement regarding immune clearance of intracellular microorganisms has foc
96  expression of latent HIV and may facilitate immune clearance of latently infected cells.
97 or more of the following processes: adaptive immune clearance of merozoites and parasitised red blood
98 he cytokine interferon (IFN)-gamma regulates immune clearance of parasitic, bacterial, and viral infe
99  FcgammaRIIA plays a significant role in the immune clearance of platelets in vivo.
100 modulatory approach could be used to enhance immune clearance of refractory fungal, mycobacterial, an
101 ing evidence for a role of chemokines in the immune clearance of rickettsiae from the vasculature.
102 iomarkers and therapeutic targets to enhance immune clearance of senescent cells and prevent cancer r
103 um-glucose co-transporter 2 (SGLT2) promoted immune clearance of senescent cells via programmed cell
104  in the retina and prevents apoptosis during immune clearance of the bacteria.
105          omega-3 provide flexible energy for immune clearance of the brain throughout the diurnal cyc
106 ntly increase as infection progresses toward immune clearance of the pathogen, suggesting a role for
107 stabilised luciferase expression, suggesting immune clearance of the transfected cells occurs in immu
108 e overexpression of 3D enhanced the adaptive immune clearance of the virus.
109                                 Accordingly, immune clearance of tumors can be facilitated by blockin
110 ver years 3-5, suggesting differences in the immune clearance of various HIV transcripts and provirus
111 nzyme B-dependent killing but may also delay immune clearance of virally infected hepatocytes.
112 anticancer therapy and on TRAIL/DR5-mediated immune-clearance of cancer cells.
113 iral cytopathic effect, 2) cell death due to immune clearance, or 3) a retreat into latency.
114              How HBV survives the subsequent immune clearance phase remains incompletely understood.
115                             The start of the immune-clearance phase (serum alanine aminotransferase l
116 levels are associated with the course of the immune-clearance phase in chronic HBV infection, and are
117                                 The start of immune-clearance phase, age at HBeAg seroconversion, and
118 tained high serum IL-12p70 levels during the immune-clearance phase.
119        The ability to persist and evade host immune clearance poses a challenge to effective antimicr
120 machine learning approach and found that the immune clearance rate of persister cells is a key featur
121 proportions of these cells, T-cell-dependent immune clearance relies on them, and abundance of their
122 re the capacity to escape senescence or even immune clearance, thereby progressing to advanced PDAC.
123 responses, Borrelia burgdorferi often evades immune clearance through largely unknown mechanisms.
124                      Malaria parasites avoid immune clearance through their ability to systematically
125 er investigate the mechanism of BcfA-induced immune clearance, we examined the role of neutrophils an
126 our retention while resisting flow shear and immune clearance, with excellent biosafety.

 
Page Top